Viral vectors remain the current standard for generating gene-modified cells, yet their use is often limited by complex manufacturing, cost, and safety considerations. As the field progresses toward scalable and regulatory-ready solutions, non-viral gene delivery has become an increasingly attractive alternative, in vivo and ex vivo.
PlasmidFactory’s Minicircle DNA technology provides a high-quality, bacterial-backbone-free vector for virus-free engineering of e.g. immune cells, stem cells and beyond. Published studies have demonstrated that minicircle-based constructs, when used in systems such as Sleeping Beauty transposition, enable efficient and stable gene transfer with reduced DNA toxicity, lower insertional risk and lower costs compared to lentiviral approaches.
This webinar will present:
The scientific principles and design advantages of minicircle DNA for cell therapy applications.
Insights from published preclinical and clinical studies employing minicircle-based cell engineering (e.g. CAR Ts, TCR Ts, CAR NKs, HSPCs).
Perspectives on scalability, GMP readiness, and the potential of minicircles in emerging in vivo gene-delivery approaches using LNP/PNP or other virus-free systems.
Join us to learn how Minicircle DNA can support safer, flexible, and efficient manufacturing of the next generation of gene-modified cell therapies.
